Special Contributing Faculty


Special Contributing Faculty


Faculty members who do not serve as dissertation mentors but who make contributions to the education of our students by teaching or serving as clinical mentors are appointed as Gerstner Sloan Kettering Special Contributing Faculty.

The following is a list of current members of the contributing faculty along with their research interests:

Cameron W. Brennan
MD, Cornell University Medical College
Genomic analysis of human and mouse gliomas and medulloblastomas.

Murray F. Brennan
MD, University of Otago
Soft Tissue Sarcoma

Jacqueline F. Bromberg
MD, PhD, The University of North Carolina at Chapel Hill
Physician-scientist who works as part of a multidisciplinary group treating patients with breast cancer

Marinela Capanu
PhD, University of Florida
Epidemiology and Biostatistics
Hierarchical models in genetic association studies, misspecification tests, and survival analysis.

Paul B. Chapman
MD, Cornell University Medical College
Metastatic melanoma

Aimee M. Crago
MD, Harvard Medical School
PhD, Cambridge University (UK)
Molecular mechanisms underlying sarcomageneis.

Hironori Funabiki
PhD, Kyoto University
Cell Biology
Studies chromosome identity, architecture, and inheritance mechanisms.

Christian Grommes
MD, RWTH Aachen Medical School (Germany)
Aberrant signaling pathways in primary central nervous system lymphomas.

John L. Humm
PhD, South Bank University
Medical Physics
Molecular imaging of cancer by PET, hypoxia, and targeted radionuclide therapies, especially with tumor-specific antibodies.

Mary L. Keohan
MD, Yale University School of Medicine
Soft Tissue Sarcoma

Mark G. Kris
MD, Cornell University Medical College
Clinical trials and translational research.

Robert J. Motzer
MD, University of Michigan Medical School
Clinical trials for metastatic renal cell carcinoma and germ cell tumors.

Larry Norton
MD, Columbia University College of Physicians and Surgeons
Breast Cancer clinical trials, tumor growth kinetics, and mathematics of metastasis.

Jae H. Park
MD, Johns Hopkins School of Medicine
Development of novel targeted therapy and application of immunotherapy in adult patients with hematologic malignancies.

Philip B. Paty
MD, Stanford University School of Medicine
Biomarkers — diagnostic, prognostic, predictive — for colorectal cancer.

Michael A. Postow
MD, New York University School of Medicine
Melanoma medical oncologist with an interest in immunotherapeutic approaches to melanoma and associated biomarker analysis.

Diane Reidy-Lagunes
MD, SUNY Downstate Medical Center
Clinician scientist with a focus on improving treatment strategies for patients with neuroendocrine tumors (NETs).

Victor E. Reuter
MD, Pedro Henriquez Urena National University (Dominican Republic)
Marker evaluation and validation in urologic cancers.

Howard I. Scher
MD, New York University School of Medicine
Mechanism-based drug development for prostate cancer.

Eytan M. Stein
MD, Northwestern University Medical School
Novel early phase therapeutics for actue myeloid leukemia, clinical trial design.

William P. Tew
MD, University of Rochester School of Medicine and Dentistry
Gynecologic cancer, developmental therapeutics, aging research/geriatic oncology.

Tiffany A. Traina
MD, Weill Cornell Medical College
Clinical trials and translational research in the field of breast cancer, specifically triple negative breast cancer and the role of the androgen receptor.

Agnes Viale
PhD, Universite de Nice-Sophia Antipolis
Genomics Core
Genomics: from microarrays to next generation sequencing.

Philip A. Watson
PhD, University of Wisconsin, Madison
Compliance and Internal Audit
Functional genomic screens to identify molecular drivers of castration resistant prostate cancer.

Harel Weinstein
DSc, Technion-Israel Institute of Technology
Computational Biology
Molecular recognition and signal transduction.

James W. Young
MD, Vanderbilt University
Human dendritic cells and the generation of immunity in cancer and transplantation.

Pat Zanzonico
PhD, Cornell University
Medical Physics
Nuclear medicine and molecular imaging research: hypoxia imaging, targeted radionuclide therapy, and small-animal imaging.